The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Cabaletta Bio Inc shares valued at $19,888 were purchased by Chang David J. on Jan 21 ’26. At $2.26 per share, Chang David J. acquired 8,800 shares. The insider’s holdings grew to 8,800 shares worth approximately $20592.0 following the completion of this transaction.
Also, Binder Gwendolyn purchased 11,312 shares, netting a total of over 24,763 in proceeds. Following the buying of shares at $2.19 each, the insider now holds 31,312 shares.
Before that, Tomasello Shawn had added 22,725 shares to its account. In a trade valued at $50,322, the Director bought Cabaletta Bio Inc shares for $2.21 each. Upon closing the transaction, the insider’s holdings increased to 22,725 shares, worth approximately $53176.5.
Analysts at Evercore ISI downgraded the stock from ‘”an Outperform”‘ to ‘”an In-line”‘ outlook in a report released in mid December. As of December 19, 2024, Wells Fargo has decreased its “an Overweight” rating to a “an Equal weight” for CABA. Earlier on October 10, 2024, UBS initiated its rating. Their recommendation was “a Buy” for CABA stock.
Analyzing CABA Stock Performance
On last trading session, Cabaletta Bio Inc [NASDAQ: CABA] rose 6.85% to $2.34. The stock’s lowest price that day was $2.18, but it reached a high of $2.35 in the same session. During the last five days, there has been a surge of approximately 8.84%. Over the course of the year, Cabaletta Bio Inc shares have dropped approximately -14.60%.
Is Cabaletta Bio Inc subject to short interest?
Stocks of Cabaletta Bio Inc saw a sharp rise in short interest on 2025-12-31 jumping by 0.68 million shares to 18.8 million. Data from Yahoo Finance shows that the short interest on 2025-11-28 was 18.11 million shares. A jump of 3.63% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 9.81 of the overall float, the days-to-cover ratio (short ratio) jumped to 9.81.
Which companies own the most shares of Cabaletta Bio Inc (CABA)?
In terms of Cabaletta Bio Inc share price expectations, FactSet research, analysts set an average price target of 14 in the next 12 months, up nearly 539.27% from the previous closing price of $2.19. Analysts anticipate Cabaletta Bio Inc stock to reach 32 by 2026, with the lowest price target being 3. In spite of this, 5 analysts ranked Cabaletta Bio Inc stock as Buy at the end of 2026. On February 05, 2024, Jefferies assigned a price target of “a Buy” to the stock and initiated coverage with a $36.
